Currently, there are no validated prognostic biomarkers to predict benefit from mFOLFIRINOX, although KRAS G12 subtype and tumor molecular classification into classical and basal-like subtypes have been used to genotype tumors.17 The gene discussed is KRAS; the disease is neoplasm.